Lumicell Introduces Further Research and Insights in Fluorescence-Guided Surgery at the Society of Surgical Oncology (SSO) Annual Meeting
View the full release here: https://www.businesswire.com/news/home/20240325761901/en/
- View the full release here: https://www.businesswire.com/news/home/20240325761901/en/
Barbara Smith, M.D, PhD., presented results from the INSITE study during the Breast Cancer Hub Zone talk during the SSO Annual Meeting 2024. - “It’s so energizing to see such a diversity of surgeons across different specialties come together to advance the collective field of surgical oncology,” said Jorge Ferrer, M.D., PhD, Chief Scientific Officer, Lumicell.
- Most recently, the FDA’s Medical Imaging Drugs Advisory Committee (MIDAC) voted in support of the benefit-risk profile of LUMISIGHT™ (pegulicianine) during its March 5, 2024 meeting .
- The FDA is expected to make a decision on Lumicell’s NDA and PMA in the near future.